Dabur India Limited · NSE:DABUR
Dabur India — Q2 FY22 Earnings Presentation
28 slides from Dabur India's earnings presentation, Nov 2, 2021
Slide 1: Exchange filing cover letter
^\^. ^!^^. ^s^f^ ^^ T^ }ur Ref: SEC/SE/2021-22 India Ltd. Date: November 02, 2021 Scrip Symbol: NSE- DABUR, BSE Scrip Code: 500096 To, Corporate Relation Department National Stock Exchange of India Ltd BSE Ltd Exchange Plaza, 5th Floor Phiroze Jeejeebhoy Towers Plot No. C/l, G Block Bandra - Kurla C
Slide 2: Results Presentation Q2 FY22
RESULTS PRESENTATION Q2 FY22 2 ND NOVEMBER 2021
Slide 3: Agenda
AGENDA 1 2 3 Q2 FY22 Q2 FY22 H1 FY22 Performance Summary Business Highlights Performance Summary 2
Slide 4: Q2 FY22 Performance Summary
1 Q2 FY22 PERFORMANCE SUMMARY
Slide 5: Q2 FY22 Performance Summary
Q2 FY22 | Performance Summary Consolidated Revenue Growth 12.0% 10% India FMCG Growth 11.9% India FMCG Volume International Business CC Growth 13.8% Growth Operating Profit Growth 9.0% Consolidated PAT Growth 4.7% 4
Slide 6: Q2 FY22 Consolidated Financials
Q2 FY22 | Consolidated Financials Revenue from Operations EBITDA PBT PAT 2-yr CAGR: 12.9% 2-yr CAGR: 12.6% 2-yr CAGR: 19.7% 2-yr CAGR: 11.9% 12.0% 9.0% 12.1% 4.7% 2,818 661 621 504 2,516 482 590 569 2,212 403 490 462 Q2 FY20 Q2 FY21 Q2 FY22 Q2 FY20 Q2 FY21 Q2 FY22 Q2 FY20 Q2 FY21 Q2 FY22 Q2 FY20 Q2
Slide 7: Domestic FMCG Growth – By Verticals
Q2 FY22 | Domestic FMCG Growth – By Verticals Q2 FY21 Sales Contribution Q2 FY22 Sales Contribution Food & Beverage Food & Beverage Healthcare 12.7% Healthcare 16.3% 33.8% 39.6% HPC HPC 47.6% 49.9% Healthcare Home & Personal Care Food & Beverage 2-yr CAGR: 19.2% 2-yr CAGR: 12.8% 2-yr CAGR: 17.3% (4.
Slide 8: International Business Performance
Q2 FY22 | International Business Performance Q2 FY21 Sales Contribution Q2 FY22 Sales Contribution Others Others International 2.2% International 2.4% 26.0% 25.9% Domestic Domestic 71.8% 71.7% International Business grew by 13.8% in CC (11.2% growth in INR terms) Q2 FY22 Constant Currency Growth % 2
Slide 9: Q2 FY22 Business Highlights
Q2 FY22 BUSINESS HIGHLIGHTS 2
Slide 10: Business Highlights - Healthcare
Q2 FY22 | Business Highlights - Healthcare Health Supplements Digestives OTC & Ethicals Growth % (13.6%) 22.7% 1.9% 2-year CAGR 21.5% 12.1% 19.4% • Dabur Glucose recorded strong • The portfolio continued to see • Driven by strong growth in double-digit growth strong momentum on the back of Honitus,
Slide 11: New Product Launches - Healthcare
Q2 FY22 | New Product Launches - Healthcare Chyawanprash Spout Dabur Honey Throat Dabur Vita Hajmola LimCola Dabur Oliv-O-Oil Pack Relief Dabur Honitus Sugar Restora Gold Agnisandeepan Churna Panchagun Tail Free 10
Slide 12: Business Highlights – Home & Personal Care
Q2 FY22 | Business Highlights – Home & Personal Care Oral Care Hair Oils Shampoo Home Care Skin & Salon Growth % 13.3% 27.9% 20.5% 25.3% (11.9%) 2-year CAGR 18.6% 9.5% 19.1% 6.1% 10.3% • Toothpaste category • Witnessed a strong • Shampoos portfolio • Robust double-digit • Excluding Sanitize witnesse
Slide 13: New Product Launches – Home & Personal Care
Q2 FY22 | New Product Launches – Home & Personal Care Dabur Aloe Vera Nourishing Gel Dabur Vatika Face Wash Range Odomos Liquid Vaporiser 12
Slide 14: Business Highlights – Food & Beverage
Q2 FY22 | Business Highlights – Food & Beverage Beverages Foods Growth % 45.0% 15.6% 2-year CAGR 17.5% 13.9% • After a smart recovery in Q1, Beverage business continued • Hommade brand continued to perform well driven by innovation and to exhibit strong momentum strong demand • In-home and out-of-ho
Slide 15: New Products Launched in Q2 FY22 International Business
New Products Launched in Q2 FY22 International Business 14
Slide 16: New Products | MENA
New Products | MENA Dermoviva Skin Food Dermoviva Face Wash Dermoviva Face Scrub Dermoviva Face Mask Hommade Range Dabur Herbolene Petroleum Jelly 15
Slide 17: New Products | MENA
New Products | MENA Dabur Honitus Herbal Lozenges Dabur Glycodab Tablets Dabur Triphala Churna Dabur Botanica Ashwagandha Dabur Botanica Immunofit Dabur Hepano Tablets 16
Slide 18: New Products | Turkey
New Products | Turkey Hobby Naturals NPDs in Egypt (Turkey) Vatika Ayurveda (USA) 17
Slide 19: H1 FY22 Performance Summary
H1 FY22 PERFORMANCE SUMMARY 3
Slide 20: H1 FY22 Consolidated Financials
H1 FY22 | Consolidated Financials Revenue from Operations EBITDA PBT PAT 2-yr CAGR: 10.0% 2-yr CAGR: 11.3% 2-yr CAGR: 16.5% 2-yr CAGR: 10.9% 20.8% 18.9% 21.3% 14.4% 5,429 1,173 1,229 942 4,485 4,496 986 823 947 1,013 766 905 H1 FY20 H1 FY21 H1 FY22 H1 FY20 H1 FY21 H1 FY22 H1 FY20 H1 FY21 H1 FY22 H1
Slide 21: H1 FY22 Domestic FMCG Growth – By Verticals
H1 FY22 | Domestic FMCG Growth – By Verticals H1 FY21 Sales Contribution H1 FY22 Sales Contribution Food & Beverage Food & Beverage Healthcare 13.5% Healthcare 17.7% 34.7% 38.6% HPC HPC 48.0% 47.5% Healthcare Home & Personal Care Food & Beverage 2-yr CAGR: 23.8% 2-yr CAGR: 8.5% 2-yr CAGR: 12.6% 10%
Slide 22: H1 FY22 International Business Performance
H1 FY22 | International Business Performance H1 FY21 Sales Contribution H1 FY22 Sales Contribution Others Others 2.2% 1.6% International International 26.1% 25.7% Domestic Domestic 71.7% 72.7% International Business grew by 22.8% in CC (18.7% growth in INR terms) H1 FY22 Constant Currency Growth % 3
Slide 23: Annexure
Annexure 22
Slide 24: Consolidated P&L | Q2 FY22 and H1 FY22
Consolidated P&L | Q2 FY22 and H1 FY22 All figures are in INR cr Q2 FY22 Q2 FY21 Y-o-Y (%) H1 FY22 H1 FY21 Y-o-Y (%) Revenue from operations 2,817.6 2,516.0 12.0% 5,429.1 4,496.0 20.8% Other Income 112.4 87.6 28.4% 197.3 159.4 23.8% Total Income 2,930.0 2,603.6 12.5% 5,626.4 4,655.4 20.9% Material C
Slide 25: Standalone P&L | Q2 FY22 and H1 FY22
Standalone P&L | Q2 FY22 and H1 FY22 All figures are in INR cr Q2 FY22 Q2 FY21 Y-o-Y (%) H1 FY22 H1 FY21 Y-o-Y (%) Revenue from operations 2,119.9 1,900.9 11.5% 4,102.7 3,391.8 21.0% Other Income 97.2 73.2 32.7% 168.3 138.1 21.9% Total Income 2,217.1 1,974.1 12.3% 4,271.1 3,529.8 21.0% 47.6% 50.0% M
Slide 26: Consolidated Balance Sheet
Consolidated Balance Sheet Particulars As at 31/09/2021 As at 31/03/2021 Particulars As at 31/09/2021 As at 31/03/2021 A Assets B Equity and Liabilities Non-current 1 Equity 1 assets (a) Equity share capital 177 177 (a) Property, plant and equipment 1,883 1,812 (b) Other Equity 7,962 7,487 (b) Capit
Slide 27: Standalone Balance Sheet
Standalone Balance Sheet Particulars As at 31/09/2021 As at 31/03/2021 Particulars As at 31/09/2021 As at 31/03/2021 A Assets B Equity and Liabilities 1 Non-current assets 1 Equity (a) Property, plant and equipment 1,217 1,131 (a) Equity share capital 177 177 (b) Capital work-in-progress 124 107 (b)
Slide 28: For more information and updates, visit
For more information and updates, visit: http://www.dabur.com/in/en-us/investor 27